<DOC>
	<DOCNO>NCT00696657</DOCNO>
	<brief_summary>This trial conduct Europe , Asia Africa . Study participant randomise evenly treatment semaglutide ( 0.1 mg QW - 1.6 mg QW , 6 treatment arm , placebo liraglutide ( 1.2 mg QD , 1.8 mg QD ) .Treatment allocation semaglutide placebo double-blind , whereas liraglutide treatment administer open-label.Primary efficacy parameter HbA1c treatment duration 12 week .</brief_summary>
	<brief_title>A Randomised Controlled Clinical Trial Type 2 Diabetes Comparing Semaglutide Placebo Liraglutide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Men womennotofchildbearing potential diagnose type 2 diabetes least three month Stable treatment regimen either metformin ( least 1500 mg ) diet exercise alone least three month HbA1c : 7.010.0 % ( inclusive ) Body weight 60 kg 110 kg Treatment insulin , GLP1 receptor agonist ( include liraglutide ) , dipeptidyl peptidase4 inhibitor , sulphonylurea , thiazolidinediones , AlphaGIs , investigational drug , within last three month Impaired liver kidney function Proliferative retinopathy maculopathy require acute treatment Clinically significant active cardiovascular disease uncontrolled treated/untreated hypertension Recurrent major hypoglycaemia hypoglycaemic unawareness Present plan use drug could interfere glucose level ( e.g . systemic corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>